YL-17231

Other Medications

EU Experimental ES Not available 2 Clinical Trials

Description

YL-17231 is an investigational medication currently being studied in clinical trials for advanced solid tumors, including colorectal cancer. It is being evaluated in Phase 1 trials to determine its safety, how the body processes the drug (pharmacokinetics), and to get early signs of whether it might be effective. The trials are being conducted in China. Researchers are looking at the drug's effects in patients whose tumors have specific characteristics, such as KRAS wild-type status and PD-L1 expression levels. YL-17231 is not yet approved for use in colorectal cancer or any other condition.

Mechanism of Action

The specific way YL-17231 works (its mechanism of action) is still under investigation. Phase 1 trials like the one studying YL-17231 are designed to understand the drug's effects on the body and its potential impact on tumors, which helps researchers determine how it might work at a molecular level.

Side Effects

Because YL-17231 is an investigational drug in early-phase trials (Phase 1) The full range of potential side effects is still being evaluated. Phase 1 trials primarily focus on safety Identifying the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). Specific side effect data from these trials are not yet widely available But like many cancer treatments Potential side effects could include common chemotherapy-related issues or effects related to the drug's specific mechanism Which is still being determined.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06096974 Phase 1
Recruiting
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
United States
NCT06078800 Phase 1
Unknown
A Study of YL-17231 in Patients With Advanced Solid Tumors
China

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials2
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
785 trials
Leucovorin
Other Medications
646 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.